Q2 2024 Scandion Oncology A/S Earnings Call Transcript
/-
Thank you very much, and welcome again to this Q2 2024 report. Next slide, please. Right, so this is a disclaimer that we will not go through. Next one. Alright. So today, we will go through the CORIST, the CORIST data. Basically, we will go through the performance. This will be done by our CFO, Johnny. And then I will end this call with the near term milestones of Scandion Oncology. Right. Shall we have the next slide, please? Right. So today, the speaker as I said earlier, is myself as a CEO and Johnny, our CFO.
Next slide. Right. So today is an important call. And the reason being that we have fully enrolled our patients into the CORIST trial. Furthermore, we have also achieved MTD. And consequently, we are in a process to finally analyze the full set of data of our CORIST clinical trial. So that's an important milestone that we have achieved at Scandion Oncology over the last few months. And I will come back to that.
With regard to PANTAX. We have released the data actually in H1 of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |